Yescarta approved in Europe for specific lymphomas

28 August 2018
2019_biotech_test_vial_discovery_big

The European Commission has granted marketing authorization for Yescarta (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

The drug was originated by US biotech Kite Pharma, which was acquired by US biotech major Gilead Sciences (Nasdaq: GILD) in an $11.9 billion deal in August 2017. Gilead’s shares were up 1.62% at $74.78 in mid-morning trading on Monday.

Axicabtagene ciloleucel was approved by the US Food and Drug Administration on October 18, 2017, and in the second quarter of this year generating sales of $68 million for Gilead.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology